SynthesisOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026
Effect of Superior Laryngeal Nerve Block for Neurogenic Cough: A Single-Arm Meta-Analysis.
Synthesis in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveWe aimed to assess cough symptom improvement following superior laryngeal nerve block (SLNB) in patients with neurogenic cough (NC). DATA SOURCES: Studies were systematically searched on PubMed, Embase, Web of Science, and Cochrane Library. REVIEW
methodsArticles reporting SLNB for the treatment of NC were included. Outcomes of interest included subjective reporting of improvement, patient-reported outcome measures, and adverse events. Mean difference (MD) was used for continuous outcomes and proportions for binary endpoints, with 95% confidence intervals (CI).
resultsEight retrospective studies involving 552 patients met inclusion criteria. The pooled proportion of subjective improvement of cough following SLNB was 74.04% (95% CI 68.61-78.81, I² = 13.6%). Patients experienced a statistically significant reduction in Cough Severity Index scores (MD -7.37, 95% CI -13.42 to -1.32, P = .02, I² = 81.7%), with the greatest reduction in those who underwent 3 or more injections (MD -10.57, 95% CI -19.37 to -1.78, I² = 33.4%, P = .02). Adverse events were minimal and self-resolving, with 17.91% and 3.35% of patients experiencing local transient and systemic transient events, respectively. Injection-limiting/serious adverse events were rare, occurring in 1.97% of patients.
conclusionOur findings suggest that SLNB may benefit a substantial number of patients, as evidenced by improvements in both subjective reports and cough-specific patient-reported outcomes, while maintaining a favorable safety profile with minimal adverse events. Additionally, patients who received multiple injections generally experienced greater reductions in cough severity. Further large-scale clinical trials are needed to confirm the efficacy and long-term effects of this treatment modality. LEVEL OF EVIDENCE: II.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.